SCHEMBL1467010

SCHEMBL1467010

O=C1COc2ccc(C(=O)c3ccccc3C(=O)NCc3cccc(Br)c3)cc2N1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.60
TSHR P16473 1/20 0.57
ALDH1A1 P00352 3/20 0.52
MAOA P21397 1/20 0.52
PARP1 P09874 2/20 0.49
KMT2A Q03164 1/20 0.48
RAF1 P04049 1/20 0.47
BRAF P15056 1/20 0.47
AKR1B1 P15121 1/20 0.46
MAPT P10636 1/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SMYD3 Q9H7B4 1/20 0.45
CYP3A4 P08684 1/20 0.45
LMNA P02545 1/20 0.44
MMP8 P22894 1/20 0.44
MMP13 P45452 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1466865 0.91 GAA (0.62) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1467069 0.90 GAA (0.71) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1468515 0.86 GAA (0.57) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1466382 0.85 GAA (0.60) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1468492 0.85 GAA (0.60) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1466178 0.85 GAA (0.62) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1466286 0.85 GAA (0.62) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1467150 0.85 GAA (0.62) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1468339 0.83 GAA (0.68) GAATSHRALDH1A1MAOAPARP1
SCHEMBL1467226 0.83 GAA (0.59) GAATSHRALDH1A1MAOAPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8697737-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2014-04-15 US disclosed
US-20110071145-A1 Raf Modulators And Methods Of Use EXELIXIS, INC. (US) 2011-03-24 US disclosed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 US disclosed
US-20080009488-A1 Raf Modulators and Methods of Use EXELIXIS, INC. (US) 2008-01-10 US disclosed
EP-1751124-A2 RAF MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005112932-A2 RAF MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009488-A1 Raf Modulators and Methods of Use BRAF, RAF1, ARAF GAA 2494/4885TSHR 3427/4885ALDH1A1 2799/4885
US-20110071145-A1 Raf Modulators And Methods Of Use BRAF, RAF1, ARAF GAA 1501/4885TSHR 2571/4885ALDH1A1 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.